The American Journal of Medicine
Volume 120, Issue 6 , Pages 525-530 , June 2007

Selective Serotonin Reuptake Inhibitor Use by Patients with Acute Coronary Syndromes

  • Roy C. Ziegelstein, MD

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md
    • Corresponding Author InformationRequests for reprints should be addressed to Roy C. Ziegelstein, MD, Department of Medicine, B-1-North, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224-2780.
    • ,
  • Jennifer Meuchel, MD

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md
    • ,
  • Thomas J. Kim, MD

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md
    • ,
  • Madiha Latif, MBBS

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md
    • ,
  • William Alvarez, PharmD

      Affiliations

    • Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Md
    • ,
  • Neela Dasgupta, MD

      Affiliations

    • Department of Medicine, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md
    • ,
  • Brett D. Thombs, PhD

      Affiliations

    • Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Md.

References 

  1. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494
  2. Serebruany VL. Selective serotonin reuptake inhibitors and increased bleeding risk: are we missing something?. Am J Med. 2006;119:113–116
  3. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost. 2004;91:119–128
  4. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci. 2005;62:159–170
  5. Nelva A, Guy C, Tardy-Poncet B, et al. Hemorrhagic syndromes related to selective serotonin reuptake inhibitor (SSRI) antidepressants (Seven case reports and review of the literature). Rev Med Interne. 2000;21:152–160
  6. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106–1109
  7. Dalton SO, Johansen C, Mellemkjaer L, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal tract bleeding: a population-based cohort study. Arch Intern Med. 2003;163:59–64
  8. Wessinger S, Kaplan M, Choi L, et al. Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment Pharmacol Ther. 2006;23:937–944
  9. Schlienger RG, Fischer LJ, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf. 2004;27:1157–1165
  10. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation. 2001;104:1894–1898
  11. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation. 2003;108:32–36
  12. Cohen HW, Gibson G, Alderman MH. Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med. 2000;108:2–8
  13. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol. 2001;52:179–184
  14. Tata LJ, West J, Smith C, et al. General population based study of the impact of tricyclic and selective serotonin reuptake inhibitor antidepressants on the risk of acute myocardial infarction. Heart. 2005;91:465–471
  15. Serebruany VL, Glassman AH, Malinin AI, et al. Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the Sertraline AntiDepressant Heart Attack Randomized Trial (SADHART) Platelet Substudy. Circulation. 2003;108:939–944
  16. Plaut D. CView. Baltimore, MD: Johns Hopkins Health System, Casemix Information Management; 2005;
  17. Cohen M, Demers C, Gurfinkel EP, et al. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997;337:447–452
  18. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction (Results of the thrombolysis in myocardial infarction (TIMI) 11B trial). Circulation. 1999;100:1593–1601
  19. Goodman SG, Fitchett D, Armstrong PW, et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003;107:238–244
  20. Wohrle J, Grebe OC, Nusser T, et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation. 2003;107:1840–1843
  21. D’Agostino RB Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265–2281
  22. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. Am J Stat Assoc. 1984;79:516–524
  23. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the twenty-sixth annual SAS users group international conference. SAS Institute, Inc., Cary, NC. 2001.
  24. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA. 2005;294:3108–3116
  25. van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ. 2001;323:655–658
  26. Celexa [package insert]. St. Louis, MO: Forest Pharmaceuticals, Inc.:2006. Available at: http://www.celexa.com/pdf/celexa_pi.pdf. Accessed March 13, 2007.
  27. Lexapro. St. Louis, MO: Forest Pharmaceuticals, Inc.:2002. Available at: http://www.fda.gov/cder/foi/label/2003/21323se1-003,se8-007,21365se8-001,se1-004_lexapro_lbl.pdf. Accessed March 13, 2007.
  28. Prozac [Medication Guide]. Indianapolis, IN: Eli Lilly and Company:2006. Available at: http://pi.lilly.com/us/prozac.pdf. Accessed March 13, 2007.
  29. Paxil [Medication Guide]. Research Triangle Park, NC: GlaxoSmithKline:2006. Available at: http://us.gsk.com/products/assets/us_paxil.pdf. Accessed March 13, 2007.
  30. Zoloft [Medication Guide]. New York, NY: Pfizer Pharmaceuticals:2006. Available at: http://www.pfizer.com/pfizer/download/uspi_zoloft.pdf. Accessed March 13, 2007.
  31. Glassman AH, O’Connor CM, Califf RM, et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. 2002;288:701–709
  32. Taylor CB, Youngblood ME, Catellier D, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. 2005;62:792–798

PII: S0002-9343(06)01486-0

doi: 10.1016/j.amjmed.2006.10.026

The American Journal of Medicine
Volume 120, Issue 6 , Pages 525-530 , June 2007

Article Tools